Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: BONZ who wrote (172)	11/22/1997 3:38:00 AM
From: Diane Leadman	Read Replies (1) \| Respond to of 1510

Bonz - the fact that the FDA is going to start approving treatment faster for life-threatening illness probably has something to do it. Whatever it is, I'm pleased. About time we got some good news. Diane.

To: BONZ who wrote (172)	11/24/1997 1:24:00 AM
From: Mark B. Martell, CCM	Read Replies (1) \| Respond to of 1510

Bonz, shouldn't you be called Captain instead? Wrong Star Trek Character. IMHO IMNR is moving up for no real reason. I sent a note to IMNR's IR department (Deb Altman) regarding my perceived lack of promised November news regarding Remune. The response was not noteworthy IMO. She stated (more or less, forgive me Deb if you read this) that we won't have any real news regarding Remune's success until May of 1998. All we know now is that all the patients in the Phase III trial are in and accounted for, with the drug being administered safely. Oh well, this stock is still a long term play. I'd hate to not be around for if and when this baby takes off.